IN2014MU01194A - - Google Patents

Info

Publication number
IN2014MU01194A
IN2014MU01194A IN1194MU2014A IN2014MU01194A IN 2014MU01194 A IN2014MU01194 A IN 2014MU01194A IN 1194MU2014 A IN1194MU2014 A IN 1194MU2014A IN 2014MU01194 A IN2014MU01194 A IN 2014MU01194A
Authority
IN
India
Prior art keywords
acceptable derivative
pharmaceutical
sulbactam
cefepime
stereoisomer
Prior art date
Application number
Other languages
English (en)
Inventor
Sachin Bhagwat
Mahesh Vithalbhai Patel
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Priority to IN1194MU2014 priority Critical patent/IN2014MU01194A/en
Priority to CN201580017231.6A priority patent/CN106900171A/zh
Priority to BR112016022439A priority patent/BR112016022439A2/pt
Priority to PCT/IB2015/050268 priority patent/WO2015150926A1/en
Priority to KR1020167027684A priority patent/KR20160130824A/ko
Priority to EP15706531.9A priority patent/EP3125887A1/en
Priority to JP2016558575A priority patent/JP2017508769A/ja
Priority to MX2016012646A priority patent/MX2016012646A/es
Priority to US15/300,113 priority patent/US20170151221A1/en
Publication of IN2014MU01194A publication Critical patent/IN2014MU01194A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
IN1194MU2014 2014-03-29 2015-01-14 IN2014MU01194A (forum.php)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IN1194MU2014 IN2014MU01194A (forum.php) 2014-03-29 2015-01-14
CN201580017231.6A CN106900171A (zh) 2014-03-29 2015-01-14 包含头孢吡肟或舒巴坦的药物组合物
BR112016022439A BR112016022439A2 (pt) 2014-03-29 2015-01-14 Composições farmacêuticas que compreendem cefepima ou sulbactama
PCT/IB2015/050268 WO2015150926A1 (en) 2014-03-29 2015-01-14 Pharmaceutical compositions comprising cefepime or sulbactam
KR1020167027684A KR20160130824A (ko) 2014-03-29 2015-01-14 세페파임 또는 술박탐을 포함하는 제약학적 조성물
EP15706531.9A EP3125887A1 (en) 2014-03-29 2015-01-14 Pharmaceutical compositions comprising cefepime or sulbactam
JP2016558575A JP2017508769A (ja) 2014-03-29 2015-01-14 セフェピムまたはスルバクタムを含む医薬組成物
MX2016012646A MX2016012646A (es) 2014-03-29 2015-01-14 Composiciones farmaceuticas que comprenden agentes antibacterianos.
US15/300,113 US20170151221A1 (en) 2014-03-29 2015-01-14 Pharmaceutical compositions comprising cefepime or sulbactam

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1194MU2014 IN2014MU01194A (forum.php) 2014-03-29 2015-01-14

Publications (1)

Publication Number Publication Date
IN2014MU01194A true IN2014MU01194A (forum.php) 2015-10-02

Family

ID=54239460

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1194MU2014 IN2014MU01194A (forum.php) 2014-03-29 2015-01-14

Country Status (9)

Country Link
US (1) US20170151221A1 (forum.php)
EP (1) EP3125887A1 (forum.php)
JP (1) JP2017508769A (forum.php)
KR (1) KR20160130824A (forum.php)
CN (1) CN106900171A (forum.php)
BR (1) BR112016022439A2 (forum.php)
IN (1) IN2014MU01194A (forum.php)
MX (1) MX2016012646A (forum.php)
WO (1) WO2015150926A1 (forum.php)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022047603A1 (en) * 2020-09-01 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Beta-lactamase inhibitors and their preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101060846A (zh) * 2004-12-02 2007-10-24 维纳斯药业有限公司 采用可用于注射的β-内酰胺酶抑制剂防止β-内酰胺酶介导抗生素抗性的成分
KR101850265B1 (ko) * 2011-05-28 2018-04-18 욱크하르트 리미티드 항균제 및 타조박탐을 포함하는 조성물
RU2569059C2 (ru) * 2011-07-26 2015-11-20 Вокхардт Лимитед Фармацевтические композиции, содержащие бета-лактамный антибиотик, сульбактам и ингибитор бета-лактамаз
KR101737167B1 (ko) * 2011-07-26 2017-05-17 욱크하르트 리미티드 술박탐 및 베타―락타마아제 저해제를 포함하는 약학 조성물
MX348974B (es) * 2011-08-27 2017-07-04 Wockhardt Ltd Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
US8796257B2 (en) * 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US20150203503A1 (en) * 2012-08-25 2015-07-23 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS

Also Published As

Publication number Publication date
KR20160130824A (ko) 2016-11-14
EP3125887A1 (en) 2017-02-08
BR112016022439A2 (pt) 2017-08-15
US20170151221A1 (en) 2017-06-01
MX2016012646A (es) 2016-10-28
WO2015150926A1 (en) 2015-10-08
CN106900171A (zh) 2017-06-27
JP2017508769A (ja) 2017-03-30

Similar Documents

Publication Publication Date Title
MY195977A (en) Heterocyclic Compounds and uses Thereof
PH12016502255A1 (en) Combination
TW201613911A (en) Heterocyclic compounds and uses thereof
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
PH12018500061A1 (en) Oxysterols and methods of use thereof
EP4279071A3 (en) Novel cannabinoid formulations
MX2016011992A (es) Derivados de piperidina-diona.
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX2018014813A (es) Composiciones antibacterianas.
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
PH12017502319A1 (en) Injectable pharmaceutical formulations of lefamulin
NZ739518A (en) Compounds useful for inhibiting ror-gamma-t
IN2014CH00840A (forum.php)
IN2014MU00859A (forum.php)
TW201613898A (en) Benzofuran analogue as NS4B inhibitor
IN2013MU03308A (forum.php)
IN2013MU03421A (forum.php)
IN2013MU03704A (forum.php)
MY202239A (en) Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
MX2016013428A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
IN2013MU03422A (forum.php)
IN2013MU03309A (forum.php)
IN2014MU01194A (forum.php)
MX2018010652A (es) Composiciones farmaceuticas.